Tuberculosis Trial, Recruiting (NCT05553236)

Tuberculosis Trial, Recruiting NCT05553236 Sponsor: University of California, San Francisco Condition: Tuberculosis

Printed from Voxsanity (voxsanity.com.au) — NCT05553236 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Tuberculosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with tuberculosis (TB) that is resistant to an important TB antibiotic called rifampicin, at a facility that is part of this study
You have had a positive TB test result from a lab sample, such as a culture, smear, or a sample taken from a testing device (confirm with trial site)

Who may not be able to join:

You are planning to move away from the area where the study is taking place during the study period
You do not agree to take part in the study
You are later found, through additional testing, to actually have TB that responds to rifampicin-type antibiotics after all — this would mean you would be removed from the study after joining (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: John Z Metcalfe, MD, PhD, University of California, San Francisco

Phone: +14152068314

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05553236

Sponsor: University of California, San Francisco

Phase: Not Applicable

Status: Recruiting

Condition: Tuberculosis

Trial contact: +14152068314

More information: https://clinicaltrials.gov/study/NCT05553236

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with tuberculosis (TB) that is resistant to an important TB antibiotic called rifampicin, at a facility that is part of this study
You have had a positive TB test result from a lab sample, such as a culture, smear, or a sample taken from a testing device (confirm with trial site)

Who may not be able to join:

You are planning to move away from the area where the study is taking place during the study period
You do not agree to take part in the study
You are later found, through additional testing, to actually have TB that responds to rifampicin-type antibiotics after all — this would mean you would be removed from the study after joining (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of California, San Francisco

Registry

ClinicalTrials.gov

Start date

1 August 2024

Est. completion

1 January 2027

Where this trial is recruiting

🇿🇦 South Africa

Primary endpoints

Number of participants with prespecified end of treatment outcomes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov